{"corpus_id":206137464,"paper_sha":"3c1574a3b31d4bbfc48b803d4be0a5f70265eb1b","doi":"10.1016/j.jhep.2018.05.024","arxiv_id":null,"pmid":30104154,"pmcid":null,"mag_id":2810470127,"dblp_id":null,"acl_id":null,"title":"Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.","year":2018,"publication_date":"2018-10-01","venue":"Journal of Hepatology","journal":{"name":"Journal of hepatology","pages":"\n          776-784\n        ","volume":"69 4"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":40,"citation_count":69,"influential_citation_count":4,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Alanine Transaminase","mj":false,"qs":[{"q":"blood","mj":true,"ui":"Q000097"}],"ui":"D000410"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Hepatitis B e Antigens","mj":false,"qs":[{"q":"blood","mj":true,"ui":"Q000097"}],"ui":"D006513"},{"d":"Hepatitis B, Chronic","mj":false,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D019694"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Logistic Models","mj":false,"ui":"D016015"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Patient Selection","mj":true,"ui":"D018579"},{"d":"World Health Organization","mj":false,"ui":"D014944"}],"chemicals":[{"n":"Hepatitis B e Antigens","ui":"D006513","reg":"0"},{"n":"Alanine Transaminase","ui":"D000410","reg":"EC 2.6.1.2"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.journal-of-hepatology.eu/article/S0168827818321020/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/37ff6cfac33f0fca929c076d9cfa788a28c46ff5","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND & AIMS\nTo eliminate hepatitis B virus (HBV) infection, it is essential to scale up antiviral treatment through decentralized services. However, access to the conventional tools to assess treatment eligibility (liver biopsy/Fibroscan®/HBV DNA) is limited and not affordable in resource-limited countries. We developed and validated a simple score to easily identify patients in need of HBV treatment in Africa.\n\n\nMETHODS\nAs a reference, we used treatment eligibility determined by the European Association for the Study of the Liver based on alanine aminotransferase (ALT), liver histology and/or Fibroscan and HBV DNA. We derived a score indicating treatment eligibility by a stepwise logistic regression using a cohort of chronic HBV infection in The Gambia (n = 804). We subsequently validated the score in an external cohort of HBV-infected Africans from Senegal, Burkina Faso, and Europe (n = 327).\n\n\nRESULTS\nOut of several parameters, two remained in the final model, namely HBV e antigen (HBeAg) and ALT level, constituting a simple score (treatment eligibility in Africa for the hepatitis B virus: TREAT-B). The score demonstrated a high area under the receiver operating characteristic curve (0.85, 95% CI 0.79-0.91) in the validation set. The score of 2 and above (HBeAg-positive and ALT ≥20 U/L or HBeAg-negative and ALT ≥40 U/L) had a sensitivity and specificity for treatment eligibility of 85% and 77%, respectively. The sensitivity and specificity of the World Health Organization criteria based on the aspartate aminotransferase-to-platelet ratio index (APRI) and ALT were 90% and 40%, respectively.\n\n\nCONCLUSIONS\nA simple score based on HBeAg and ALT had a high diagnostic accuracy for the selection of patients for HBV treatment. This score could be useful in African settings.\n\n\nLAY SUMMARY\nLimited access to the diagnostic tools used to assess treatment eligibility (liver biopsy/Fibroscan/hepatitis B virus DNA) has been an obstacle to the scale up of hepatitis B treatment programs in low- and middle-income countries. Using the data from African patients with chronic HBV infection, we developed and validated a new simple diagnostic score for treatment eligibility, which only consists of hepatitis B virus e antigen and alanine aminotransferase level. The diagnostic accuracy of the score for selecting patients for HBV treatment was high and could be useful in African settings.","claims":[{"public_id":"cl_08e2a38945feafe244b74bb420fa5426","status":"active","text":"A simple treatment-eligibility score for hepatitis B virus infection, TREAT-B, was derived from hepatitis B e antigen and alanine aminotransferase level.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_08e2a38945feafe244b74bb420fa5426"},{"public_id":"cl_6d0e5cebac418a6e6e4a3d369c94efaa","status":"active","text":"A threshold score of 2 or above yielded 85% sensitivity and 77% specificity for identifying treatment eligibility.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6d0e5cebac418a6e6e4a3d369c94efaa"},{"public_id":"cl_4e446cd6759be4ab77fcd3bd4d0b914c","status":"active","text":"Compared with the World Health Organization APRI-and-ALT criteria, the new score had lower sensitivity but substantially higher specificity for treatment eligibility.","confidence":0.91,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4e446cd6759be4ab77fcd3bd4d0b914c"},{"public_id":"cl_7cf816e3674b206f9844c3659964421d","status":"active","text":"The score achieved high diagnostic accuracy in external validation, with an area under the receiver operating characteristic curve of 0.85 (95% CI 0.79-0.91).","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7cf816e3674b206f9844c3659964421d"}],"concepts":[{"public_id":"co_1671c3877c36731104cbd096291d7e06","status":"active","name":"World Health Organization criteria","description":"The WHO treatment-eligibility criteria based on APRI and ALT.","types":["guideline criteria"],"aliases":["WHO criteria"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1671c3877c36731104cbd096291d7e06"},{"public_id":"co_35aee15de115bd933a3a6d1b85845fa0","status":"active","name":"sensitivity","description":"The proportion of treatment-eligible patients correctly identified by the score or criteria.","types":["performance metric"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_35aee15de115bd933a3a6d1b85845fa0"},{"public_id":"co_5b20bd92b7e9bf7e1f3aa82aa63321ad","status":"active","name":"TREAT-B","description":"A simple diagnostic score for identifying hepatitis B patients eligible for antiviral treatment in African settings.","types":["diagnostic score","method"],"aliases":["treatment eligibility in Africa for the hepatitis B virus"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5b20bd92b7e9bf7e1f3aa82aa63321ad"},{"public_id":"co_6c21a3978672f2052c426ba40afd1e23","status":"active","name":"hepatitis B e antigen","description":"A viral antigen used in the score as one of the predictors of treatment eligibility.","types":["biomarker"],"aliases":["HBeAg"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6c21a3978672f2052c426ba40afd1e23"},{"public_id":"co_84d217357494961395c800611e82dfb2","status":"active","name":"alanine aminotransferase","description":"A liver enzyme level used in the score as one of the predictors of treatment eligibility.","types":["biomarker"],"aliases":["ALT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_84d217357494961395c800611e82dfb2"},{"public_id":"co_8c4e63cdcb4819d56524662d1f1c1b10","status":"active","name":"area under the receiver operating characteristic curve","description":"A summary measure of diagnostic discrimination used to assess the score's performance.","types":["evaluation metric"],"aliases":["AUC","AUROC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8c4e63cdcb4819d56524662d1f1c1b10"},{"public_id":"co_8d77249724836b3be755fd50ce565e39","status":"active","name":"external cohort","description":"An independent validation sample of HBV-infected Africans from Senegal, Burkina Faso, and Europe.","types":["validation cohort"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8d77249724836b3be755fd50ce565e39"},{"public_id":"co_a4de7b813fea7a03002110d7155e59c8","status":"active","name":"specificity","description":"The proportion of treatment-ineligible patients correctly identified by the score or criteria.","types":["performance metric"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a4de7b813fea7a03002110d7155e59c8"},{"public_id":"co_aca025c4d0916ec0004f047466828c1d","status":"active","name":"APRI","description":"The aspartate aminotransferase-to-platelet ratio index, a noninvasive fibrosis-related criterion used in WHO guidance.","types":["clinical index"],"aliases":["aspartate aminotransferase-to-platelet ratio index"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aca025c4d0916ec0004f047466828c1d"},{"public_id":"co_fc6617492d5d1667c209718b1a005e0e","status":"active","name":"hepatitis B virus treatment eligibility","description":"The clinical determination of whether a patient should start antiviral therapy for hepatitis B.","types":["clinical decision"],"aliases":["HBV treatment eligibility"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fc6617492d5d1667c209718b1a005e0e"}],"external_ids":{"DOI":"10.1016/j.jhep.2018.05.024","ArXiv":null,"PubMed":30104154,"PubMedCentral":null,"MAG":2810470127,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.journal-of-hepatology.eu/article/S0168827818321020/pdf","landing_url":"https://www.semanticscholar.org/paper/37ff6cfac33f0fca929c076d9cfa788a28c46ff5","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632776,"paper_uid":"d58c97ea-1e28-4ebe-8828-9a3fbeda63f4","canonical_identity":{"paper_id":632776,"paper_uid":"d58c97ea-1e28-4ebe-8828-9a3fbeda63f4","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/206137464"}